These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7972347)

  • 1. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
    Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
    Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
    Schiwy W; Heath WR; Delini-Stula A
    J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine.
    Volz HP; Faltus F; Magyar I; Möller HJ
    J Affect Disord; 1994 Mar; 30(3):209-17. PubMed ID: 8006247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
    Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
    J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
    Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
    Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.
    Kennedy SH; Goldbloom DS; Ralevski E; Davis C; D'Souza JD; Lofchy J
    J Clin Psychopharmacol; 1993 Dec; 13(6):415-22. PubMed ID: 8120155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brofaromine in elderly major depressed patients--a comparative trial versus imipramine.
    Möller HJ; Volz HP
    Eur Neuropsychopharmacol; 1993 Dec; 3(4):501-10. PubMed ID: 8111223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind comparison of moclobemide and tranylcypromine in depression.
    Heinze G; Rossel L; Gabelic I; Galeano-Munoz J; Stabl M; Allen SR
    Pharmacopsychiatry; 1993 Nov; 26(6):240-5. PubMed ID: 8127928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
    Fritze J; Becker T; Ziegler V; Laux G; Riederer P
    Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are there any differences in the safety and efficacy of brofaromine and imipramine between non-elderly and elderly patients with major depression?
    Volz HP; Müller H; Möller HJ
    Neuropsychobiology; 1995; 32(1):23-30. PubMed ID: 7566519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
    Kennedy SH
    J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year.
    Möller HJ; Volz HP
    J Affect Disord; 1992 Nov; 26(3):163-72. PubMed ID: 1460166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder.
    Nardi AE; Lopes FL; Valença AM; Freire RC; Nascimento I; Veras AB; Mezzasalma MA; de-Melo-Neto VL; Soares-Filho GL; King AL; Grivet LO; Rassi A; Versiani M
    Psychiatry Res; 2010 Feb; 175(3):260-5. PubMed ID: 20036427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled double-blind study of femoxetine and amitriptyline in patients with endogenous depression.
    Reebye PN; Yiptong C; Samsoon J; Schulsinger F; Fabricius J
    Pharmacopsychiatria; 1982 Sep; 15(5):164-9. PubMed ID: 6757983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory depression treated with high doses of monoamine oxidase inhibitor.
    Guze BH; Baxter LR; Rego J
    J Clin Psychiatry; 1987 Jan; 48(1):31-2. PubMed ID: 3804984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moclobemide versus tranylcypromine in the treatment of depression.
    Rossel L; Moll E
    Acta Psychiatr Scand Suppl; 1990; 360():61-2. PubMed ID: 2248075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.